Unlocked Insights: Forecasting the Alzheimer’s Drug Development Pipeline

As the biopharma industry advances, understanding the commercial potential and competitive dynamics of Alzheimer’s drug development is more critical than ever. Join our speakers for an exclusive session on this rapidly evolving landscape.

In this webinar, we will explore how investors and corporate strategy teams can leverage AI-powered research tools and forward-looking consensus estimates to assess emerging Alzheimer’s therapies. We will examine key players, pipeline progress, and market forecasts to uncover actionable insights using S&P Capital IQ Pro and Visible Alpha.

Apply the learning, so you can:

• Understand how funding flows and investor priorities are evolving.
• Track leading therapies, emerging entrants, and key clinical milestones.
• Evaluate the total addressable market using product-level estimates.
• Identify signals of success in Phase I/II trials to assess the long-term viability of new therapies.
• Monitor trends and support strategic decisions using AI-powered tools on S&P Capital IQ Pro.